Business
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH Expected in 2H22 Phase 1
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Conference call scheduled for 4:30 p.m. ET today\nCompletion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH Expected in 2H22 Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Ongoing; Results Expected by Year-End Quarter-End Cash Balance of $185M Provides Runway Through Multiple Clinical CatalystsSAN DIEGO, April 27, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2022, and provided an update on its clinical pipeline and other corporate developments.\n\n \n \n \n \n \n \n\n \nHighlights from the Quarter Ended March 31, 2022, and Other Recent Events:\n\"The first quarter of 2022 was a period of continued momentum at Viking, as we expanded our clinical portfolio and advanced our existing programs,\" stated Brian Lian, Ph.D., chief executive officer of Viking. \"Early in the quarter, we announced the initiation of clinical development with our newest pipeline program, VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, for the treatment of various metabolic disorders. We expect to report the initial results from a Phase 1 trial of this compound later in the year. During the quarter, we also continued enrollment in the ongoing Phase 2b study of our lead program VK2809 in patients with biopsy-confirmed NASH and fibrosis. We expect to complete enrollment in this study in the second half of 2022. With our rare disease program, VK0214, for X-linked adrenoleukodystrophy, during the first quarter we initiated activities to satisfy the FDA's request for an additional pre-clinical study. We expect to submit the requested data to the Agency in the second quarter of this year and look forward to resuming clinical development of this important program. We are advancing each of these programs while maintaining continued financial discipline. We believe our quarter-end cash balance of $185 million provides a runway extending through important data readouts from each of our clinical programs.\"\nPipeline and Corporate Highlights\nPhase 2b VOYAGE study evaluating VK2809 for the treatment of NASH continues enrolling pati...